EP
FOLD

Edgestream Partners’s Amicus Therapeutics FOLD Stock Holding History

Edgestream Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-47,631
Closed -$273K – 945
2025
Q2 		$273K Sell
47,631
-10,765
-18% -$69.5K 0.01% 793
2025
Q1 		$477K Buy
+58,396
New +$540K 0.02% 705
2024
Q4 		– Sell
-258,605
Closed -$2.76M – 935
2024
Q3 		$2.76M Buy
258,605
+167,735
+185% +$1.83M 0.12% 306
2024
Q2 		$901K Sell
90,870
-179,294
-66% -$1.84M 0.04% 546
2024
Q1 		$3.18M Buy
270,164
+250,734
+1,290% +$3.21M 0.16% 216
2023
Q4 		$276K Sell
19,430
-85,967
-82% -$976K 0.02% 737
2023
Q3 		$1.28M Sell
105,397
-159,938
-60% -$2.06M 0.1% 319
2023
Q2 		$3.33M Buy
+265,335
New +$3.15M 0.3% 60

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Edgestream Partners's FOLD Position: Q3 2025 in Review

Edgestream Partners sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 47,631 shares — an estimated $273K sold.

Edgestream Partners first reported a position in FOLD in Q2 2023 and held it in 8 quarters. The position peaked at $3.33M in Q2 2023. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Edgestream Partners reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Edgestream Partners sold 47,631 Amicus Therapeutics shares in Q3 2025, an estimated $273K.
  • Edgestream Partners first reported a position in Amicus Therapeutics in Q2 2023 and held it in 8 quarters.
  • Edgestream Partners's Amicus Therapeutics position peaked at $3.33M in Q2 2023.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Edgestream Partners's 13F filing for Q3 2025, filed 12 Nov 2025.